6 results about "Cholesterol absorption" patented technology

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The invention belongs to the technical field of health-care foods, and particularly relates to a health-care food for assisting in regulating blood fat, blood pressure and blood sugar and a preparation method of the health-care food. A multistage pellet system is constructed by utilizing a phytosterol solid dispersion system, a nitrate-citrulline slow release system and a propionate-fermented fiber colon targeting system. Phytosterol is rapidly dissolved out of the pellet A at the upper section of the stomach and intestine, cholesterol absorption is competed, and the intestinal mucosa environment is optimized; the pellet B slowly releases beet nitrate and L-citrulline in the small intestine, and NO is stably supplied to improve vasodilation; the pellet C releases propionate and fermented fiber in a targeted manner through the colon, regulates blood sugar through short-chain fatty acid and reversely enhances an NO pathway, so that bidirectional synergy is realized; besides, the conflict of hydrophilic and hydrophobic components is eliminated through the HPMC-PVP co-loaded solid dispersion, the crosslinking degree of alginate gel beads and the loading proportion of propionate are controlled to avoid acidic interference, the bioavailability of active components is remarkably improved, and dynamic synergistic regulation of blood fat, blood pressure and blood sugar is achieved.

The present application belongs to the technical field of feed additive, and particularly relates to a compound fatty acid preparation for promoting chicken growth, and a preparation method and application thereof. The compound fatty acid preparation for promoting chicken growth is mainly composed of the following raw materials in parts by weight: 3-6 parts of stigmasterol, 2-4 parts of campesterol, 10-20 parts of linoleic acid, 12-24 parts of tributyrin, 1-2 parts of emulsifier, 3-5 parts of soybean phospholipid, 3-5 parts of protective agent, and 30-80 parts of water. The combination of stigmasterol and campesterol can significantly improve the targeted release efficiency of linoleic acid and tributyrin. The released butyric acid can activate the mitochondrial beta-oxidation pathway of intestinal epithelial cells, significantly improve the efficiency of tricarboxylic acid cycle, and enhance the intestinal barrier function. The phytosterol can also competitively inhibit the NPC1L1 transporter, reduce the intestinal cholesterol absorption, direct the energy to the growth demand, thereby improving the daily weight gain of broilers and reducing the feed-meat ratio.

The invention relates to the technical field of feed additives, in particular to a feed regulating agent for reducing egg cholesterol, which comprises the following components in parts by mass: 8-12 parts of phytosterol ester; 5 to 8 parts of chitosan oligosaccharide; 15 to 20 parts of soybean lecithin; 3-5 parts of tea polyphenol; 3-5 parts of choline chloride; 2 to 4 parts of soy isoflavone; 5-10 parts of inulin; 1 to 2 parts of inositol; 2 to 3 parts of compound probiotics; and 30-50 parts of a carrier. According to the scheme, the cholesterol is further reduced by about 10% compared with the prior art by utilizing a cholesterol absorption mechanism from the perspective of blocking cholesterol absorption through component synergy, and the cholesterol content is only about 60% of that of normally bred and produced eggs.

The invention belongs to the technical field of bioactive peptides and medicines, and discloses a bioactive peptide composition with a blood fat reducing effect and application thereof.The composition comprises a first peptide component A and a second peptide component B. The first peptide component A is a low-molecular-weight peptide component derived from soybean protein enzymolysis products, and the second peptide component B is a low-molecular-weight peptide component derived from soybean protein enzymolysis products. The second peptide component B is a medium-low molecular weight peptide component derived from a walnut meal proteolysis product, and the second peptide component B and the second peptide component B are compounded according to a specific mass ratio to form the synergistic blood fat reducing composition. Through differential dipeptide component design, the synergistic effect on cholesterol absorption and lipid metabolism regulation is achieved, and the composition has a good blood fat reducing effect and can be used for preparing related products for regulating blood fat, improving lipid metabolism and assisting in preventing or improving hyperlipemia.